Skip to content
Efmoroctocog alfa
Elocta (efmoroctocog alfa) is a fusion protein pharmaceutical. Efmoroctocog alfa was first approved as Elocta on 2015-11-18. It has been approved in Europe to treat hemophilia a.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemophilia aD006467EFO_0007267D662—32310
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemophilia bD002836D67————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEFMOROCTOCOG ALFA
INNefmoroctocog alfa
Description
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line.
Classification
Fusion protein
Drug classFc fusion protein
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1270012-79-7
RxCUI1543095
ChEMBL IDCHEMBL4297945
ChEBI ID—
PubChem CID—
DrugBankDB11607
UNII ID7PCM518YLR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Elocta - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Elocta - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Elocta - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 118 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
369 adverse events reported
View more details